BioMark Diagnostics Inc
Biomark Diagnostics Inc., an oncology focused company, develops cancer diagnostic platform to detect, monitor, and treat cancer. The company invests in and develops liquid biopsy metabolic panel assay for early stage diagnosis of lung cancer. It has a strategic partnership with Rubix LS to develop diagnostic tools to enhance lung cancer screening and improve breast cancer screening program for wo… Read more
BioMark Diagnostics Inc (BMKDF) - Total Assets
Latest total assets as of December 2024: $876.63K USD
Based on the latest financial reports, BioMark Diagnostics Inc (BMKDF) holds total assets worth $876.63K USD as of December 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
BioMark Diagnostics Inc - Total Assets Trend (2014–2024)
This chart illustrates how BioMark Diagnostics Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
BioMark Diagnostics Inc - Asset Composition Analysis
Current Asset Composition (March 2024)
BioMark Diagnostics Inc's total assets of $876.63K consist of 18.4% current assets and 81.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 14.4% |
| Accounts Receivable | $43.03K | 4.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2014–2024)
This chart illustrates how BioMark Diagnostics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: BioMark Diagnostics Inc's current assets represent 18.4% of total assets in 2024, a decrease from 100.0% in 2014.
- Cash Position: Cash and equivalents constituted 14.4% of total assets in 2024, down from 100.0% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2014.
- Asset Diversification: The largest asset category is accounts receivable at 4.0% of total assets.
BioMark Diagnostics Inc Competitors by Total Assets
Key competitors of BioMark Diagnostics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ADCNF
OTCGREY:ADCNF
|
USA | $4.51 Billion |
|
Berry Genomics Co Ltd
SHE:000710
|
China | CN¥2.34 Billion |
|
Malaysian Genomics Resource
KLSE:0155
|
Malaysia | RM20.70 Million |
|
NSN Co. Ltd
KQ:031860
|
Korea | ₩60.96 Billion |
|
JOONGANG DNM Co.Ltd
KQ:051980
|
Korea | ₩121.79 Billion |
|
GeneMatrix Inc
KQ:109820
|
Korea | ₩28.03 Billion |
|
Genoray Co. Ltd
KQ:122310
|
Korea | ₩125.67 Billion |
|
Green Cross Lab Cell Corporation
KQ:144510
|
Korea | ₩565.79 Billion |
BioMark Diagnostics Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - BioMark Diagnostics Inc generates 0.15x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - BioMark Diagnostics Inc is currently not profitable relative to its asset base.
BioMark Diagnostics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.10 | 0.28 | 0.58 |
| Quick Ratio | 0.10 | 0.28 | 0.58 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-1.36 Million | $ -982.16K | $ -448.50K |
BioMark Diagnostics Inc - Advanced Valuation Insights
This section examines the relationship between BioMark Diagnostics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 7.72 |
| Asset Growth Rate (YoY) | 48.7% |
| Total Assets | $1.09 Million |
| Market Capitalization | $8.41 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values BioMark Diagnostics Inc's assets at a significant premium ( 7.72x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: BioMark Diagnostics Inc's assets grew by 48.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for BioMark Diagnostics Inc (2014–2024)
The table below shows the annual total assets of BioMark Diagnostics Inc from 2014 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-03-31 | $1.09 Million | +48.70% |
| 2023-03-31 | $732.29K | -50.24% |
| 2022-03-31 | $1.47 Million | +54.43% |
| 2021-03-31 | $952.94K | +49.53% |
| 2020-03-31 | $637.29K | +1739.66% |
| 2019-03-31 | $34.64K | -33.05% |
| 2018-03-31 | $51.75K | +30.76% |
| 2017-03-31 | $39.57K | +17.19% |
| 2016-03-31 | $33.77K | -85.34% |
| 2015-03-31 | $230.34K | +150.36% |
| 2014-03-31 | $92.00K | -- |